Lv7
4010 积分 2021-02-08 加入
Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy
22天前
已完结
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
25天前
已关闭
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
25天前
已完结
Clinical and translational attributes of immune-related adverse events
28天前
已完结
Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy
3个月前
已完结
New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy
4个月前
已完结
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
4个月前
已关闭
Wishing for a No-Show
5个月前
已完结
Mechanisms of adaptive resistance to targeted therapy in RET-aberrant cancers
5个月前
已完结
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
7个月前
已完结
皖公网安备34019202002308
